ImmuPharma PLC announce the appointment of Dr Tim Franklin, Chief Operating Officer, to the Board of Directors. Tim has worked with ImmuPharma for over three years, initially as a consultant and more recently was appointed as Chief Operating Officer in November 2020. Tim's key responsibilities include working closely with ImmuPharma's clinical team and scientific advisors, as the Company looks to further progress its wider drug development portfolio, both through clinical development and partnering opportunities. In addition, Tim will lead the relationship with Avion Pharmaceuticals, as the Company advances Lupuzor™ through its Phase 3 trial and regulatory processes involved in the ultimate approval of the drug. Tim has over 30 years' experience in the biopharmaceutical industry. He worked in clinical research, sales & marketing, and global strategic marketing for Warner Lambert, Wellcome and SmithKline Beecham. He later moved to the capital markets where he became a top-ranked pharmaceuticals analyst at Dresdner Kleinwort investment bank. He applied his experience to stock selection at hedge funds and advised several small biotechnology companies on corporate and commercial strategy and access to capital.